Articles > Popular publications > PR Newswire press releases > April-June 2006 > Wednesday, April 19

Article: Type 1 Diabetes Patients on Technosphere Insulin Showed HbA1c Improvements, Low Post-Prandial Glucose Fluctuations, and Weight Loss.

Article from:
PR Newswire
Article date:
April 19, 2006
Copyright

VALENCIA, Calif., April 19 /PRNewswire-FirstCall/ -- MannKind Corporation today announced results from a Phase 2 clinical study of inhaled insulin in people with Type 1 diabetes. The study was designed to evaluate whether inhaled insulin delivered using the MannKind Technosphere(R) Insulin System showed similar safety and efficacy at controlling blood sugar based on dosing regimens commonly used in the every day management of diabetes, when compared to patients treated with insulin aspart (NovoLog(R)), which is an injected rapid-acting insulin analog. These findings are the first disclosure of these results and will be included in the company's webcast today, details ... 







Read all of this article with a FREE trial
















Related newspaper, magazine, and journal articles:









  




 

    

 
 
   
 


   
  
  Article: MannKind Reports Positive Data from a Phase 3 Clinical Study of ...

  
  PR Newswire; 
  September 16, 2008 ;  
  
  
 
  700+ words
... ... inferiority to a rapid-acting insulin analog VALENCIA, Calif ... prandial inhalations of Technosphere Insulin (the TI group) versus ... Study Highlights Technosphere Insulin, compared to a rapid-acting insulin analog, showed ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Technosphere/Insulin therapy properties presented ...

  
  Diabetes Week; 
  October 4, 2004 ;  
  
  
 
  700+ words
... ... delivery and glucose control with its Technosphere/Insulin system that are not available from ... diabetologist, described the ability of Technosphere/Insulin to produce a rapid increase in blood ... blood stream. In addition, the Technosphere/Insulin system was shown to have an effect ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: MannKind makes $175M placing.(Technosphere Insulin ...

  
  Pharma Marketletter; 
  August 8, 2005 ;  
  
  
 
  700+ words
... ... intends to use the net proceeds from the financing primarily to fund the continuing development program for the Technosphere Insulin System, which is currently in Phase III clinical trials in the USA and Europe. They are also expected to be ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: MannKind Provides Update on Technosphere Insulin ...

  
  PR Newswire; 
  November 10, 2004 ;  
  
  
 
  700+ words
...MannKind Corporation today announced at the CIBC World Markets Fifteenth Annual Healthcare Conference that it recently held an "End of Phase 2" meeting with U.S. Food and Drug Administration (FDA) officials to discuss the Company's Technosphere(R) Insulin System, which is under development to







   
 




  




 

    

 
 
   
 


   
  
  Article: Technosphere inhaled insulin offers advantages.(Endocrinology)

  
  Internal Medicine News; 
  November 15, 2006 ;  
  
  
 
  700+ words
... ... product, called the Technosphere Insulin System, is currently ... mealtime use of either Technosphere insulin (54) or the injected rapid-acting insulin analog aspart (56 ... of 9.01% with Technosphere insulin, compared with a ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar ...

  
  PR Newswire; 
  June 6, 2009 ;  
  
  
 
  700+ words
... ... safety of mealtime pramlintide, rapid-acting insulin or both agents in patients with type ... three times daily with mealtime rapid-acting insulin, when either agent was added to basal ... compared with 11 percent of rapid-acting insulin patients. An A1C of 7 percent or less ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar ...

  
  Diabetes Week; 
  June 22, 2009 ;  
  
  
 
  700+ words
... ... safety of mealtime pramlintide, rapid-acting insulin or both agents in patients with type ... three times daily with mealtime rapid-acting insulin, when either agent was added to basal ... compared with 11 percent of rapid-acting insulin patients. An A1C of 7 percent or less ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Insulin allergy induced by short-acting and ...

  
  Diabetes Week; 
  November 8, 2004 ;  
  
  
 
  587 words
... ... induced by short-acting and intermediate-acting insulin but not by long-acting insulin in a recent issue of the International Journal ... urticaria after injection of intermediate-acting insulin for diabetes mellitus. She had human insulin ... 







   
 

























 



 





 






Newsweek
Harper's Magazine
The Washington Post
Chicago Tribune
Crain's Chicago Business
PRNewswire
Pediatric News
The Nation
Advertising Age
The Economist (US)
A FREE trial gives you access to over 80 million articles!
Access over 6,500 publications with a FREE trial!


  



Find articles, research, and archives